ライフサイエンスコーパス: maleate

1 oduce high end-group fidelity poly(propylene maleate).

2 er with dimethyl fumarate than with dimethyl maleate.

3 mide/timolol maleate and pilocarpine/timolol maleate.

4 ctive serotonin uptake inhibitor fluvoxamine maleate.

5 n on the intraocular distribution of timolol maleate.

6 dration half-reactions using citraconate and maleate.

7 beta,gamma-imido)triphosphate (AMP-PNP), and maleate.

8 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate.

9 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate].

10 -dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate].

11 of NMDA receptors with dizocilpine hydrogen maleate (1 microm) prevented both OGD- and glutamate-med

12 tudied fatty Zucker rats given rosiglitazone maleate (50 micromol/kg diet; n = 8) for 9-12 weeks (tre

13 e dicarboxylate linkers, these compounds are maleate (7), allene-1,3-dicarboxylate (10), cis,cis-muco

14 With scrupulously pure dimethyl maleate a 2.8:1 endo:exo mixture of maleate DA adducts i

15 ydro-5H-dibenzo[a,d]cyclophenptan-5,10-imine maleate), a noncompetitive NMDAR antagonist, confirmed t

16 ture of fumarase C with beta-(trimethylsilyl)maleate, a cis substrate for fumarase, has led to the di

17 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate] abrogated this effect.

18 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate affected both morphine tolerance and neuronal ap

19 combination dispersible tablet of arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187

20 A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaqui

21 As indexed by MK801 (dizocilpine hydrogen maleate), an open channel blocker, this potentiation was

22 ety of a combination of 150 mg of arterolane maleate and 750 mg of piperaquine phosphate (AM-PQP) in

23 samples were prepared from chlorpheniramine maleate and microcrystalline cellulose (Avicel) of diffe

24 products, consisting of dorzolamide/timolol maleate and pilocarpine/timolol maleate.

25 agonist (serotonin, 5-carboxamidotryptamine maleate, and RO-600175) dose responses were characterize

26 oidal anti-inflammatory drugs, rosiglitazone maleate, and the p53 rescue drug CP-31398.

27 -dibenzo[a,d]cyclohepten-5-10-imine hydrogen maleate] and stationary fluctuation analysis of AMPA rec

28 ntramolecular hydrogen bond in the gas-phase maleate anion are in a range of 14-28 kcal/mol depending

29 se (the barrier for the hydrogen transfer in maleate anion is only 0.2 kcal/mol at the QCISD(T)/6-311

30 n (by 1.5-2 times) in the complexed hydrogen maleate anion relative to that in the naked anion.

31 e intramolecular hydrogen bond in Z-hydrogen maleate anion with respect to the normal hydrogen bond i

32 With dimethyl maleate as the starting material, facile stereoselective

33 aceutical ingredient (API), chlorpheniramine maleate, at the 2% m/m (4 mg) level.

34 Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Penn

35 ihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine maleate] before memory reactivation subsequently reduced

36 cids (adipate, malonate, methylmalonate, and maleate), biogenic amines, nucleotide derivatives, pheno

37 -dibenzo[a,d]cylohepten-5, 10-imine hydrogen maleate blocked the additional elevation in taurine asso

38 istinct from interaction of macrophages with maleated bovine serum albumin, collagen, laminin, and fi

39 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), but neither DA receptor antagonists [SCH-23390

40 M(-1) were determined for both phthalate and maleate carboxylates to the bis-(acetylguanidinium)ferro

41 (2-cyanophenyl)piperazinyl-3-methylbenzamide maleate caused a reversible decrease in postsynaptic GAB

42 The dicarboxylic acid maleate (cis-butenedioic acid) was not an inhibitor of o

43 tereospecificity in the reaction with methyl maleate comes from a less hindered coordination around t

44 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate compared with wild-type controls.

45 gy differences between the E- and Z-hydrogen maleates complexed to Me4N+, Et4N+, and Bu4N+ cation are

46 tment of 14 with HOAc in commerical dimethyl maleate (contains 5% dimethyl fumarate) leads to a nearl

47 hydronaphthalene hydrobromide, or PD 168,077 maleate (D(2)-like, D(2), D(3), and D(4) receptor agonis

48 dimethyl maleate a 2.8:1 endo:exo mixture of maleate DA adducts is still obtained.

49 he actions of 2 other GSH depleters, diethyl maleate (DEM) and buthionine sulphoximine (BSO), only 1

50 LY-ar cells treated with diethyl maleate (DEM) or diamide, agents that deplete cellular t

51 Cells treated for 1 h with 1 mM diethyl maleate (DEM) showed a 34 and 53% decrease in GSH and DN

52 xemia, mice were treated with either diethyl maleate (DEM), a glutathione-depleting agent, or buthion

53 were modified by treating cells with diethyl maleate (DEM), D,L-buthionine sulfoximine (BSO), or tert

54 -tributyl phosphorotrithioate (DEF), diethyl maleate (DEM), piperonyl butoxide (PBO) and cyclosporin

55 epletion by 1 hour pretreatment with diethyl maleate (DEM), which conjugates GSH by the GSH-S-transfe

56 ine sulphoximine (BSO; 7.2 mmol/kg), diethyl maleate (DEM; 4.2 mmol/kg), paracetamol (APAP; 3.5 and 1

57 Arg25 in the double mutant, was protected by maleate demonstrating the presence of an additional site

58 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate did not prevent induction of the thalamic LTP, s

59 hydronaphthalene hydrobromide and PD 168,077 maleate did not produce such an effect, indicating the i

60 r, 0.25-fold; 4 hours, 0.45-fold) of timolol maleate drug concentrations in intraocular tissues (aque

61 azobenzene derivatives, with maleimides and maleate esters.

62 Quantitative isomerization of the cis-maleate form of all polymers affords the trans-fumarate

63 Methergine (methylergonovine maleate) has been advocated for postdural puncture heada

64 confidence interval, 0.63-1.57); fluvoxamine maleate, hazard ratio = 0.98 (95% confidence interval, 0

65 arly equimolar mixture of fumarate- (15) and maleate-IBF Diels-Alder adducts (16 and 17), indicating

66 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate in juvenile (P35) and young adult (P56) rats.

67 Reactive oxygen species-inducing diethyl maleate increased glutathione levels and (18)F-FASu upta

68 ts: Reactive oxygen species-inducing diethyl maleate increased glutathione levels and (18)F-FASu upta

69 Maleate increased urinary MCP-1 protein and mRNA more th

70 NMDA antagonists [AP5 and MK801 (dizocilpine maleate)] indicating glutamate signaling is involved in

71 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate], indicating that deprivation reduced transmitte

72 ruption of tubular morphology during diethyl maleate-induced oxidative stress in an organotypic three

73 dro-3-methyl-5-phenyl-1H-3-benzazepine-7- OL maleate) inhibited the prolonged increase in MPC phospho

74 the effect of Y-27632 on diminished timolol maleate intraocular penetration in NZW rabbits.

75 Inhibition by IMP and maleate is consistent with a chemical mechanism for SAIC

76 Rosiglitazone maleate is the second approved oral hypoglycemic agent o

77 The unreactive substrate analogue, maleate, is used to induce closure.

78 with the nonhallucinogenic lisuride hydrogen maleate (LHM) and was absent in receptor null-mutant mic

79 Maleate lowered the rate of reduction of the wild-type e

80 ), succinate (suc(2-)), glutarate (glu(2-)), maleate (male(2-)) and fumarate (fum(2-)) anions were st

81 adacidin, l-malate, succinate, fumarate, and maleate), maleate was by far the best inhibitor, competi

82 ts metformin hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patient

83 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801) and by the antagonists of NR2B receptor

84 to the NMDA receptor antagonist dizocilpine maleate (MK-801) and measuring MK-801-induced disinhibit

85 The NMDA receptor antagonists dizocilpine maleate (MK-801) and phencyclidine also increase cell de

86 hydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine maleate (MK-801) blocked the reinstatement of Pavlovian

87 to the NMDA receptor antagonist dizocilpine maleate (MK-801) during periadolescence [from postnatal

88 ith the NMDA receptor antagonist dizocilpine maleate (MK-801) for 24 h before birth also caused an in

89 in vivo, because intraperitoneal dizocilpine maleate (MK-801) injection in young adult rats resulted

90 ntrathecal NMDA-receptor blocker dizocilpine maleate (MK-801) on the peripheral immune response itsel

91 -dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK-801) prevented cell death, although the non-

92 ihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) to investigate the effects of enhancing

93 periments examined the effect of dizocilpine maleate (MK-801), a noncompetitive N-methyl-Daspartate (

94 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), a noncompetitive NMDA receptor antagon

95 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801), a well characterized use-dependent blo

96 sulfamoylbenzo(f)quinoxaline and dizocilpine maleate (MK-801), also suppressed calcium oscillations,

97 udy compared amnestic effects of dizocilpine maleate (MK-801), an NMDA receptor antagonist, and nitro

98 titive NMDA receptor antagonist, dizocilpine maleate (MK-801), on spatial working memory during devel

99 hydro-5H-dibenzo[a,d]-cyclohepten-5,10imin e maleate (MK-801), tritiated kainate, and tritiated amino

100 hydro-5H-dibenzo[a,d]-cyclohepten-5,10imin e-maleate (MK-801), tritiated kainate, and tritiated amino

101 -dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801).

102 hydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate (MK-801)] or non-NMDA [CNQX or 4-(8-methyl-9H-1,

103 Blockade of NMDARs with dizocilpine hydrogen maleate (MK-801, 20 microM) had a negligible effect on r

104 -dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801; hydrogen maleate) on 24-h ischemia-indu

105 g the non-competitive antagonist dizocilpine maleate (MK801) arrested the developmental decrease in e

106 Postnatal injection of dizocilpine maleate (MK801), a specific NMDA antagonist, has been sh

107 MDA receptor antagonist dizocilpine hydrogen maleate (MK801).

108 The maleate moiety in 7-oxabicyclo[2.2.1]hept-2,5-diene-2,3-

109 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate]) N-methyl-d-aspartate antagonists partially dec

110 erogeneous mouse models of ARF were studied: Maleate nephrotoxicity, unilateral ureteral obstruction,

111 Neither oxidants (sulforaphane and diethyl maleate) nor reducing compounds (N-acetyl-l-cysteine and

112 ,10-imine hydrogen maleate (MK-801; hydrogen maleate) on 24-h ischemia-induced CRH concentrations in

113 etic inhibitory pharmacologic agent, timolol maleate, on the magnitude of nearwork-induced transient

114 5 mM fumarate alone, or 0.1 mM 5'-AMP + 5 mM maleate or 5 mM succinate.

115 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate or CNQX.

116 These analogues were converted into their maleate or hydrochloride salts 13.

117 e 4 was perfused with l-NAME plus pyrilamine maleate or l-NAME plus cimetidine.

118 sed with either the H1 antagonist pyrilamine maleate or the H2 antagonist cimetidine.

119 ibenzo [a,d] cyclohepten-5,10-imine hydrogen maleate] or the GABA(A) receptor potentiator phenobarbit

120 Rosiglitazone maleate (P < 0.05) and CP-31398 (P < 0.05) significantly

121 nyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate; P-9236) (54) displayed a pharmacological profil

122 inone and commercially available fumarate or maleate precursors is reported.

123 and urine samples from mice with intrarenal (maleate), prerenal (endotoxemia), or postrenal (ureteral

124 raocular penetration of administered timolol maleate presumably due to increased systemic elimination

125 ihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate] provided no protection at any age.

126 tronidazole, phenobarbital, chlorpheniramine maleate, pyridoxine and riboflavin.

127 nternal H-bonding energies for a series of Z-maleate/R4N+ salts (R = CH3, C2H5, CH3CH2CH2CH2) range f

128 h L-buthionine-(S,R) sulfoximine and diethyl maleate, revealed no changes in the cells' ability to tr

129 f adenosine A2a agonist 1 in the form of its maleate salt 2 was achieved.

130 vivo porcine corneal penetration of timolol maleate, sotalol hydrochloride, or brinzolamide incubate

131 ydro-5H-dibenzo [a,d]-cyclohepten-5,10-imine maleate], the curtailed WT and KO responses were indisti

132 e of the present work was to implant timolol maleate (TM) loaded ethyl cellulose nanoparticle-laden r

133 All subjects received timolol maleate to block the sympathetic nervous system and beta

134 Treating mice with diethyl maleate to deplete tissue thiols significantly impaired

135 lyzed the hydration of the minimal substrate maleate to form d-malate.

136 ydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (/) trapping, whole-cell responses to NMDA were

137 pH buffers without an aminosulfonate moiety (maleate, Tris, and bicarbonate).

138 hyperpolarized long-lived state in dimethyl maleate using thiol conjugate addition.

139 However, maleate was an excellent inducer of DctA expression.

140 l-malate, succinate, fumarate, and maleate), maleate was by far the best inhibitor, competitive with

141 hydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine maleate was included in the patch pipette.

142 ocyte function, and GSH depletion by diethyl maleate was shown previously to inhibit expression of NF

143 Ca2+ buffers (5 to 20 mmol/L ADA, citrate or maleate) were introduced into the SR by exposing the cel

144 rovision of either exogenous H2O2 or diethyl maleate, which raises intracellular H2O2 levels.

145 lular uptake after OS induction with diethyl maleate, with and without anti-xCT small interfering RNA